Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease
- PMID: 18378855
- PMCID: PMC4544761
- DOI: 10.1161/HYPERTENSIONAHA.107.105395
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease
Abstract
The aim of the present cross-sectional study was to investigate whether activation of the renin-angiotensin system in renovascular disease affects the cytochrome P450 omega/omega-1 hydroxylase (20-hydroxyeicosatetraenoic acid [20-HETE]) and epoxygenase (epoxyeicosatrienoic acids [EETs]) pathways of arachidonic acid metabolism in vivo, each of which interacts with angiotensin II. Plasma concentration and urinary excretion of 20-HETE and EETs and their metabolites, dihydroxyeicosatrienoic acids, were measured in urine and plasma by mass spectrometry in 10 subjects with renovascular disease, 10 with essential hypertension, and 10 healthy normotensive subjects (control subjects), pair-matched for gender and age. Vascular and renal function were evaluated in all of the subjects. Plasma 20-HETE was highest in subjects with renovascular disease (median: 1.20 ng/mL; range: 0.42 to 1.92 ng/mL) compared with subjects with essential hypertension (median: 0.90 ng/mL; range: 0.40 to 2.17 ng/mL) and control subjects (median: 0.45 ng/mL; range: 0.14 to 1.70 ng/mL; P<0.05). Plasma 20-HETE significantly correlated with plasma renin activity in renovascular disease (r(s)=0.67; n=10; P<0.05). The urinary excretion of 20-HETE was significantly lower in subjects with renovascular disease (median: 12.9 microg/g of creatinine; range: 4.4 to 24.9 microg/g of creatinine) than in control subjects (median: 31.0 microg/g of creatinine; range: 11.9 to 102.8 microg/g of creatinine; P<0.01) and essential hypertensive subjects (median: 35.9 microg/g of creatinine; range: 14.0 to 72.5 microg/g of creatinine; P<0.05). Total plasma EETs were lowest, as was the ratio of plasma EETs to plasma dihydroxyeicosatrienoic acids, an index of epoxide hydrolase activity, in renovascular disease (ratio: 2.4; range: 1.2 to 6.1) compared with essential hypertension (ratio: 3.4; range: 1.5 to 5.6) and control subjects (ratio: 6.8; range: 1.4 to 18.8; P<0.01). In conclusion, circulating levels of 20-HETE are increased and those of EETs are decreased in renovascular disease, whereas the urinary excretion of 20-HETE is reduced. Altered cytochrome P450 arachidonic acid metabolism may contribute to the vascular and tubular abnormalities of renovascular disease.
Figures



Similar articles
-
Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function.Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:2-7. doi: 10.1016/j.prostaglandins.2013.01.002. Epub 2013 Jan 17. Prostaglandins Other Lipid Mediat. 2013. PMID: 23333581 Free PMC article. Review.
-
Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology.Prostaglandins Other Lipid Mediat. 2003 Oct;72(1-2):51-71. doi: 10.1016/s1098-8823(03)00077-7. Prostaglandins Other Lipid Mediat. 2003. PMID: 14626496 Review.
-
Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease.Atherosclerosis. 2012 Jun;222(2):530-6. doi: 10.1016/j.atherosclerosis.2012.03.022. Epub 2012 Mar 27. Atherosclerosis. 2012. PMID: 22503544 Free PMC article.
-
Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats.J Hypertens. 2010 Mar;28(3):582-93. doi: 10.1097/HJH.0b013e328334dfd4. J Hypertens. 2010. PMID: 19940786 Free PMC article.
-
Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs.Anal Biochem. 2001 May 1;292(1):115-24. doi: 10.1006/abio.2001.5044. Anal Biochem. 2001. PMID: 11319825
Cited by
-
Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function.Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:2-7. doi: 10.1016/j.prostaglandins.2013.01.002. Epub 2013 Jan 17. Prostaglandins Other Lipid Mediat. 2013. PMID: 23333581 Free PMC article. Review.
-
Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.J Hypertens. 2016 Oct;34(10):2008-25. doi: 10.1097/HJH.0000000000001029. J Hypertens. 2016. PMID: 27428043 Free PMC article.
-
Circadian Variation in Vasoconstriction and Vasodilation Mediators and Baroreflex Sensitivity in Hypertensive Rats.J Circadian Rhythms. 2019 Oct 14;17:10. doi: 10.5334/jcr.185. J Circadian Rhythms. 2019. PMID: 31673274 Free PMC article.
-
Regulation of CYP2J2 and EET Levels in Cardiac Disease and Diabetes.Int J Mol Sci. 2018 Jun 29;19(7):1916. doi: 10.3390/ijms19071916. Int J Mol Sci. 2018. PMID: 29966295 Free PMC article. Review.
-
20-HETE and blood pressure regulation: clinical implications.Cardiol Rev. 2014 Jan-Feb;22(1):1-12. doi: 10.1097/CRD.0b013e3182961659. Cardiol Rev. 2014. PMID: 23584425 Free PMC article. Review.
References
-
- McGiff JC, Quilley J. 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure. Curr Opin Nephrol Hypertens. 2001;10:231–237. - PubMed
-
- Sarkis A, Lopez B, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Curr Opin Nephrol Hypertens. 2004;13:205–214. - PubMed
-
- Elbekai RH, El-Kadi AOS. Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther. 2006;112:564–587. - PubMed
-
- Garovic VD, Textor SC. Renovascular hypertension and ischemic nephropathy. Circulation. 2005;112:1362–1374. - PubMed
-
- Quilley J, McGiff JC. Multiple roles of eicosanoids in blood pressure regulation. In: Lipp GYH, Hall J, editors. Comprehensive Hypertension. Philadelphia, PA: Mosby Elsevier; 2007. pp. 377–395.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical